ArticleTherapeutic advances in hematology2025

Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study.

Steffen Koschmieder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.